17. Exploiting Loopholes in Regulation
Pharmaceutical companies took advantage of regulatory gaps and weaknesses in drug approval and post-market surveillance processes. By leveraging these loopholes, they secured rapid approval for new opioid formulations and evaded robust monitoring. This strategy, documented by PBS, enabled companies to push more products to market and sustain high sales, even as evidence of harm mounted across the country.
